Guselkumab (Tremfya) 1st IL-23 inhibitor to be FDA approved for subcutaneous induction in adults with ulcerative colitis

Guselkumab (Tremfya) 1st IL-23 inhibitor to be FDA approved for subcutaneous induction in adults with ulcerative colitis https://t.co/KaZVzyomeY

Links:

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adul… https://buff.ly/OH9Vkzl

Sep-22-2025

Topics